Sugi Predict

Sugi Predict / Compounds / SCHEMBL485056

SCHEMBL485056

SCHEMBL485056

CC(C)(C)OC(=O)N1CCC2(CCC(O)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 8/20 0.50
▸ HPGD P15428 1/20 0.48
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ RECQL P46063 1/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ CHRM2 P08172 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ EPHX2 P34913 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19785288 0.91 GPR119 (0.46) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL24697198 0.91 CYP11B2 (0.48) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL20460883 0.91 GPR119 (0.46) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL25547105 0.87 GPR119 (0.50) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL346995 0.86 USP2 (0.56) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL1707965 0.86 GPR119 (0.44) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL20077138 0.86 GPR119 (0.49) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL16054753 0.86 GPR119 (0.49) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL23536248 0.86 GPR119 (0.52) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL14662117 0.85 CHRM2 (0.46) GPR119HPGDUSP2SMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 — — EP disclosed
US-20250333417-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-30 — — US disclosed
WO-2025201532-A1 NOVEL PEGYLATION COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (SHANGHAI) LIMITED., CO. (CN) 2025-10-02 — — WO disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 — — US disclosed
WO-2024073475-A9 CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) 2025-04-24 — — WO disclosed
CN-119841832-A Compounds having SMARCA2 inhibitory effect and uses thereof 杭州中美华东制药有限公司 2025-04-18 — — CN disclosed
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-10 — — US disclosed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 — — WO disclosed
WO-2025021182-A1 CYP11A1 INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2025-01-30 — — WO disclosed
EP-4466260-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2024-11-27 — — EP disclosed
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 — — US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 — — US disclosed
EP-2411381-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-02-01 — — EP disclosed
US-8049012-B2 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-11-01 — — US disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 — — US disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 — — WO disclosed
EP-1899303-B1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-09-15 — — EP disclosed
US-20090227613-A1 Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors NEURO SEARCH A/S (DK) 2009-09-10 — — US disclosed
EP-1899303-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-03-19 — — EP disclosed
WO-2007000465-A1 NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231327-A1 Substituted Spiro-Amide Compounds BDKRB1, BDKRB2, REN GPR119 206/4885HPGD 386/4885USP2 4864/4885
US-20090227613-A1 Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 GPR119 187/4885HPGD 789/4885USP2 1709/4885
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 GPR119 4342/4885HPGD 1488/4885USP2 618/4885
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A GPR119 770/4885HPGD 3777/4885USP2 2743/4885
US-20100249095-A1 Substituted Spiro-amide Compounds BDKRB1, BDKRB2, REN GPR119 206/4885HPGD 386/4885USP2 4864/4885
US-20250333417-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GPR119 2426/4885HPGD 3843/4885USP2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.